Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Recruiting 4Active not recruiting 4Unknown 2Completed 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Breast Neoplasms 705Carcinoma, Non-Small-Cell Lung 473Prostatic Neoplasms 423Neoplasms 384Multiple Myeloma 266Colorectal Neoplasms 257Lung Neoplasms 245Neoplasm Metastasis 234Melanoma 219Leukemia, Myeloid, Acute 193Ovarian Neoplasms 189Pancreatic Neoplasms 177Squamous Cell Carcinoma of Head and Neck 160Carcinoma, Renal Cell 146Recurrence 144Lymphoma 144Glioblastoma 142Lymphoma, Non-Hodgkin 136Stomach Neoplasms 128Triple Negative Breast Neoplasms 127Leukemia, Lymphocytic, Chronic, B-Cell 123Brain Neoplasms 123Carcinoma, Hepatocellular 122Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Urinary Bladder Neoplasms 115Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Lymphoma, Large B-Cell, Diffuse 104Sarcoma 103Lymphoma, Follicular 100

Interventions

Paclitaxel 2Topotecan 1Platinum 1Etoposide 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × SCLC × Clear all
NCT06616532 2026-05-22

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Biotheus Inc.

Phase 3 Active not recruiting
404 enrolled
Thoracic

SCLC

NCT07145333 2025-09-08

Drug-SNP

Medicine Invention Design, Inc

Phase 2/3 Active not recruiting
600 enrolled
Thoracic

SCLC

NCT05844150 2025-03-12

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Biotheus Inc.

Phase 2 Active not recruiting
50 enrolled
Thoracic

SCLC

NCT05879068 2024-12-18

A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC

Biotheus Inc.

Phase 2 Active not recruiting
99 enrolled
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡